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Summary Recent preclinical and clinical data suggest that TP53 status and TP53 mutations may be important in determining tumour
aggressiveness and therapy response. In this study we investigate the feasibility of a structural and quantitative analysis of TP53 on fine-
needle aspiration (FNA) material obtained from 31 consecutive female patients with breast carcinoma, enrolled in a primary chemotherapy
protocol. Tumours were screened for p53 protein overexpression and TP53 mutations (exons 5-8) using immunocytochemistry, polymerase
chain reaction-single-strand conformation polymorphism (PCR-SSCP) and DNA sequencing analyses, and finally using fluorescence in situ
hybridization (FISH) analysis. Positive nuclear staining was identified in six cases whereas mutations were detected in nine. Although the
immunoreactive pattern fitted fully with the characterized TP53 mutation type, the considerable number of null p53 mutations (i.e. four)
coupled with the lack of information regarding the localization of TP53 mutations make immunocytochemistry an inadequate indicator of TP53
function deregulation. Combining molecular and FISH analyses, we detected three cases with TP53 deletion and one case with deletion and
mutation. Finally, DNA static-image analysis performed on 29 cases showed aneuploidy in 26 cases, which included all TP53-mutated cases.
The present results show that FNA may assist clinical decisions by allowing the evaluation of a variety of biological parameters relevant for
prognosis and treatment planning.
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The fine-needle aspiration (FNA) technique represents one of the
most effective and versatile methodologies that contribute to the
diagnosis and the management ofbreast cancer. Over recent years,
the field of FNA application has expanded, and currently FNA
spans the diagnostic assessment of palpable and non-palpable
nodules and contributes to management decisions at surgical and
medical levels (Masood et al, 1990; Layfield, 1992). In fact, FNA
has largely replaced frozen sections and, in cases candidated to
primary chemotherapy, provides hormonal receptor assessment as
well as other useful pathobiological parameters with an efficiency
that equals that of histology (Thomas et al, 1990; Dowell et al,
1994; Leong et al, 1996).
Recent clinical evidence supports a critical role of TP53 status
in providing prognostic information (Kovach et al, 1996; Sjogren
et al, 1996). Preclinical (Lowe et al, 1993, 1994; Wahl et al, 1996)
and clinical data (Bergh et al, 1995; Aas et al, 1996; Fricker, 1996;
Sjogren et al, 1996) suggest that TP53 status and TP53 mutation
types may be important not only in determining tumour aggres-
siveness but also in the response to therapy. In fact, there is
increasing evidence that tumours lacking normal TP53 function
are clinically more aggressive as they acquire a selective growth
advantage becoming more resistant to ionizing radiations and
some widely used anti-cancer drugs.
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Here, we investigate the feasibility of an extensive structural
and quantitative analysis of the TP53 gene using PCR-SSCP and
sequencing, FISH, together with DNA static-image analyses on
FNA material obtained from patients with clinical features
matching primary chemotherapy criteria.
The present results show that FNA may further assist clinical
decisions by allowing a simultaneous evaluation of a variety of
biological parameters relevant for prognosis and by supplying
precise molecular data that are important in treatment planning.
This is of particular value in a primary chemotherapy setting, as
complete tumour regression may occur and FNA-based pre-
chemotherapy information may represent the only available infor-
mation unaffected by therapy.
MATERIALS AND METHODS
Patients and materials
Thirty-one consecutive female patients (age range 25-71 years,
mean 53 years) with primary breast carcinoma examined by FNA
who entered a primary chemotherapy protocol (doxorubicin and
paclitaxel) were chosen for the present study. According to the
Tumour Node and Metastases (TNM) classification (UICC, 1992;
pp. 103-109), three cases were T4bNlM1, ten cases T4bNlMO,
three cases T3N1MO, one case T3N1M1, two cases T3NOMO, four
cases T2NlMO and eight cases T2NOMO. Two patients (case nos.
24 and 21) came from breast cancer-prone families.
Material was obtained in each case by 10-15 rapidback and forth
motions of fine needle (21 gauge) within the nodule, performed
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Table 1 Correlation between full TP53 analysis, FISH, DNA content, grading and proliferation index in 31 consecutive FNA
ICC Molecular data FISH data SIAS
Case noJ Grade Mibi Mab SSCP DNA sequencing TP53 Ploidy
age (years) Do-7 Exons 5-8 NTchange/AA allelic
substitution loss
Intronic base substitution
wt
wt
wt
wt
wt
wt
wt
Mutation exon 6
t-c
Codon 194
CTT-CCT/Leu-Pro
Mutation exon 6 Codon 220
TAT-TGT/Tyr-Cys
wt
wt
wt
wt
Mutation exon 7
wt
wt
wt
wt
Mutation exon 5
wt
wt
wt
Mutation exon 7
wt
Mutation exon 5
Mutation exon 5
wt
Mutation exon 6
Mutation exon 7
Mutation exon 8
Codon 249
AGG-ACG/Arg-Thr
Codon 176
1-bp Deletion
Codon 245
GGC-TGC/Gly-Cys
Codon 176
1-bp ins/stop
Codon 175
CGC-CAC/Arg-Hys
Codon 213
CGA-CGG/polymorphism
Codon 248
CGG-TGG/Arg-Trp
Codon 266
GGA-GAA/Gly-Glu
No
No
No
No
No
No
NE
No
No
No
NE
NE
No
NE
No
No
No
No
Yes
Yes
NE
NE
No
No
Yes
No
NE
A
A
Aa
A
A
A
A
A
A
Aa
D
ND
A
D
A
ND
A
A
A
A
A
D
A
A
A
A
Aa
Yes A
No A
No
No
A
A
aTetraploid. A, aneuploid; D, diploid; wt, wild type; ICC, immunocytochemistry; FISH, fluorescence in situ hybridization; SIAS, static-image analysis
system; SSCP, single-strand conformation polymorphism; AA, amino acid; ND, not done; NE, not evaluable.
during a single pass. The aspirated material was partly smeared on
slides and routinely processed according to Papanicolaou and May
Grunwald-Giemsa (MGG) techniques and was partly smeared on
poly-L-lysine-coated slides, which were fixed in acetone and imme-
diately processed for p53 and MIB 1 immunostaining. The smears
not used immediately were stored at-20'C. The remaining material
was diluted in 1 ml ofphosphate-buffered saline (PBS) and used as
cell suspension for DNA extraction.
Immunostaining
Detection of p53 protein expression was performed using the
monoclonal antibody D07 diluted 1:1000 (Ylem, Avezzano, AQ,
Italy). Cell proliferation was evaluated by using MIB 1 diluted
1:100 (Dako, Glostrup, Denmark). Both monoclonal antibodies
(MAbs) were detected by means of the streptavidin-biotin
immunoperoxidase method (streptavidin HRP; streptavidin horse
radish peroxidase). Briefly, smears were treated with 0.3%
hydrogen peroxide for 20-30 min to suppress the endogenous
peroxidase. Thereafter, normal human serum (2%) was applied for
30 min as a suppressor serum. The slides were then incubated
overnight at 4°C with the primary antibody. After several brief
rinses, the biotinylated secondary antibody (30 min) and strepta-
vidin HRP were applied in succession. The preparations were then
developed in a 3,3-diaminobenzidine solution, counterstained in
Carazzi's haematoxylin, dehydrated and mounted.
p53 staining was interpreted as positive when the nuclear
staining was more than 10%. The MIB proliferative activity was
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10-30
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> 30
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+
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4/65
5/44
6/30
7/43
8/71
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10/41
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14/38
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20/44
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22/60
23/46
24/25
25/53
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27/46
28/76
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31/44
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G3
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G3
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G2
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G2
G3
G3
G3
> 30
> 30
> 30
10-30
> 30
> 30
<10
> 30
> 30
> 30
> 30
> 30
> 30
> 30
> 30
> 30
+
+
+
0 Cancer Research Campaign 1998TP53analyses and DNA content in breast FNA 127
indicated as a percentage of immunoreactive nuclei: less than
10%, from 10% to 30%, more than 30%, corresponding to low,
intermediate and high immunostaining respectively.
Additional information (data not shown) was acquired using an
immunocytochemical panel routinely applied to FNA, encom-
passing hormonal receptors and the protein encoded by the Bcl2
gene. Assessment of oestrogen receptor (ER) and progesterone
receptor (PGR) was carried out as previously described (Frigo et
al, 1995) and of bcl2 protein by Mab bcl-2, 124 diluted 1:100
(Dako) as detailed above. Overall, hormonal receptor-positive
cases accounted for 36% (12 out of 31). Bcl2 expression was
highly associated with hormonal receptor positivity: all receptor-
positive cases were bcl2 positive; nonetheless, 20% of receptor-
negative cases were bcl2 positive (Alsabeh et al, 1996). All but
one (case no. 24) ofthe bcl2-positive cases were p53 negative.
DNA analysis
Five-hundred-microlitre aliquots of PBS cell suspension were
digested by proteinase K (0.6 gl of 10 mg ml-' proteinase K per
100gl of cell suspension) and submitted to phenol extractions
following standard procedures.
Exons 5-8 were initially amplified by nested PCR amplification
(primer sequences are available upon request). A 1-pl aliquot of
the amplification products diluted 1:100 was used as DNA
template for single-strand conformation polymorphism analysis
(SSCP), as described by Donghi et al (1993). PCR-amplified
exons showing abnormal SSCP migration were subjected to direct
DNA sequencing using the AmpliCycle Sequencing kit (Perkin-
Elmer Cetus, Branchburg, NJ, USA). For sequencing assays,
genomic DNA was amplified by nested PCR as for SSCP analysis.
Amplified fragments were purified on 2% low-melting-point
agarose gels. The purified DNA fragments were used directly for
sequence analysis. Each sequence reaction was performed at least
twice, analysing separate amplifications.
Dual-colour FISH
Thirty-one FNA samples were analysed: three were frozen smears,
one was a cytospin from frozen material in PBS suspension, four
were archival cytological smears stained with May Griinwald-
Giemsa (MGG) and the remaining were Papanicolaou (PAP)-
stained smears. Archival cytological smears stained with PAP or
MGG were destained and treated before in situ hybridization,
essentially according to Cajulis et al (1996). The biotinylated
probe p53 (TP53) (Oncor, Gaithersburg, MD, USA) was cohy-
bridized with the digoxigenin-labelled chromosome 17 a-satellite
(D17Z1) (Oncor) according to Lichter et al (1990) and the manu-
facturer's recommendations. The biotinylated probe p53 was
detected by two layers of avidin-FITC (Vector), and chromosome
17 a-satellite by one layer ofrhodamine-labelled anti-digoxigenin
(ab) (Boehringer Mannheim). Slides were then counterstained by
DAPI (4,6-diamidino-2-phenylindole dihydrochloride hydrate).
The slides were observed at 1000 x magnification. At least 100
well-defined nuclei were analysed for each hybridization. The
sample was scored as deleted or polysomic only when at least 30%
of the considered cells showed deletion of TP53 or polysomy of
chromosome 17, as false monosomies or deletions could be due to
insufficient hybridization efficiency (Sauter et al, 1996). Images
were acquired with a cooled CCD camera (Photometrics, Tucson,
AZ, USA) coupled to a Zeiss fluorescence microscope and
controlled by a Power Macintosh 710/800. Frames of the nuclei
were taken separately using the IPLab Spectrum (Signal Analytics)
software package; the images were then pseudocoloured and
merged using the Gene Join software (Ried et al, 1992).
DNA content image analysis (IA)
For IA MGG-stained smears were used: coverslips were removed
with xylene and smears destained with 1% hydrochloric acid in
70% ethanol, refixed in 10% neutral formalin for 1 h and then
Feulgen stained according to the directions of the ESACP
Consensus Meeting (Bocking et al, 1995). Briefly, after hydrolysis
in SN hydrochloric acid 22°C for 1 h, specimens were rinsed in
distilled water for 5 min, stained in basic fuchsin Schiff-Feulgen
reagent at 25°C for 60 min, rinsed in running water and then in
freshly prepared sulphur dioxide. The specimens were then dehy-
drated in ethanol and xylene and mounted in coverslipping resin.
Ploidy analysis was performed using the Cires-Vidas imaging
system (Zeiss, Kontron Elektronik, Oberkochen, Germany).
From 180 to 221 cancer cells were examined, and at least 50
diploid rat hepatocytes were used as an extemal standards refer-
ence for each case.
Results of the cytophotometric DNA measurements, on the
basis of the obtained histograms, were expressed as diploid and
aneuploid. For each case, the malignancy index (MI) was calcu-
lated as the product of 2c deviation index (2cDI) per Sc exceeding
rate (ScER) (Bocking et al, 1984) (data not shown).
RESULTS
The obtained results are reported in Table 1.
Morphology
Morphological diagnosis was consistent with breast carcinoma in
all cases.
Cytological grading, performed according to a modified
(reverse) Black's scheme (Fisher et al, 1980), yielded the
following distribution: grade I, 1 out of 31 cases (3.2%); grade II,
9 out of 31 cases (29%); grade III, 21 out of31 cases (67.7%).
Immunocytochemistry (ICC)
p53
Six out of 31 (19%) cases tumed out to be p53 reactive with the
number ofimmunostained nuclei exceeding 70% in all cases.
MIB1
High MIB1 immunostaining (> 30%) was identified in 26 out of
29 cases (89%).
MIB1 vs cytologicalgrading
In all but one G3 (18 out of 19 cases, 94%) and in all but one G2
(eight out of nine, 88%), a high immunostaining was observed.
The GI case (case no. 22) showed a low MIB1 immunostaining
(<10%). In two cases (case nos. 12 and 15), MIBI immuno-
staining was not evaluable.
Frequency and spectrum of p53 gene mutations
Nested PCR-SSCP analysis of exons 5-8 was performed success-
fully on all the 31 cases included in this study. Eleven (35%) ofthe
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Figure 1 Case no. 20. Nucleotide sequence analysis of a portion of TP53 exon 5 from tumour DNA (B). The mutated sequence (B) is compared with the wild-
type exon 5 sequence from normal control DNA (A). Tumour sample (B) shows the deletion of one base. The deleted base is indicated in heavy type in A or by
A in B. In case no. 20 (B), in spite of LOH detected by FISH analysis, the mutated sequence (B) shows the presence of a faint normal sequence due to the
inevitable presence of small portions of non-tumoral components in the samples. Interphase breast cancer nuclei analysed by FISH (C) for the detection of
TP53 and chromosome 17 copy number; the green spots correspond to the TP53 gene and the red one to the chromosome 17 pericentromeric region. FISH
results show the deletion of TP53 related to the deletion of the whole chromosome 17
tested tumours showed an abnormal SSCP pattern and were all
confirmed as mutated by direct DNA sequencing. Table 1 shows
the details regarding the genetic changes identified by DNA
sequencing analysis.
The position and incidence ofthe mutations were distributed as
follows: three mutations were located in exon 5, three in exon 6,
three in exon 7, one in exon 8 and one in intron 6. Eight were
missense mutations: seven resulted in an amino acid substitution;
the remaining one revealed a neutral polymorphism at codon 213,
exon 6, which does not result in a change in amino acid sequence
(CGA -* CGG, Arg Arg) (Carbone et al, 1991; Elledge et al,
1993; Bems et al; 1996). Missense mutations included six transi-
tions (one at CpG dinucleotides) and two transversions. Six of the
seven (86%) amino acid substitutions detected in our series
occurred at mutational hotspot codons (codons 175, 194, 220, 245,
248 and 249) located in evolutionary highly conserved regions
(Greenblatt et al, 1994).
Two of the 11 mutations were non-missense mutations,
including a 1-bp deletion at codon 176 and a 1-bp insertion at
codon 176. Both these situations change the translation frame and
lead to the appearance of a premature stop codon, resulting in an
early chain termination during translation. Furthermore, in one
case, a base substitution was found at 15 bp downstream of the 3'
end of exon 6. This intronic alteration, to the best of our knowl-
edge, should not affect TP53 gene expression.
The observed neutral polymorphism at codon 213 (case no. 29)
and intronic base substitution (case no. 1) were not recorded as
mutations in the correlations specified below of molecular data
with cytological grading, ICC and IA analysis data.
Molecularanalysis vs cytologicalgrading
Eight out of the nine (88%) mutated cases and 13 out of the 22
(59%) wild-type cases showed high nuclear grade (G3), indicating
a significant association (Table 1).
Molecularanalysis vs ICC
p53 immunoreactivity correlated with the type of gene mutation.
All but one (83%) ofthe ICC-positive cases presented a missense
mutation that leads to an amino acid change; only one case (no. 6)
had a wild-typep53 gene. The ICC-negative cases included a dele-
tion, an insertion and only one missense mutation. The association
between missense mutations and ICC was statistically significant
(P = 0.0007, Fisher's exact test).
FISH analysis
Seventeen cases were evaluable for both TP53 and chromosome
17 content, seven only for TP53 content and seven were not
evaluable at all. Chromosome 17 pericentromeric signals were
detectable in only 17 slides, this may be due to a problem offixa-
tion and/or conservation ofthe slides before FISH. Moreover, p53
probe was detected with two layers of avidin-FITC as a chromo-
some 17 a-satellite with only one layer of rhodamine-labelled
anti-digoxigenin (ab) to avoid background artifacts.
Four out of 24 cases evaluable for TP53 content showed the
deletion of one TP53 allele (cases nos. 19, 20, 25, 28). One of
them was also mutated (case no. 19). Nine out of 17 cases evalu-
able for chromosome 17 content were polysomic and one was
monosomic (data not shown).
DNA (IA)
The analysis was performed on 29 cases. In two cases, insufficient
material was available (Table 1). Twenty-six out of twenty-nine
cases (89%) were aneuploid, of which three were hypertetraploid,
whereas 3 out of 29 (10%) were diploid.
In the aneuploid tumours, MI ranged from 0.32 to 7759.44
(mean 446.13, median 27.45) (data not shown).
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IA vs molecularanalysis
Comparing ploidy results with molecular data, all cases with TP53
mutations were aneuploid.
IA vs MIB1 and cytological grading
Comparing ploidy results with MIB I immunostaining, 24 out of
26 (92%) aneuploid cases showed a high MIB1 immunostaining.
Furthermore, all aneuploid cases were G3 or G2 with high MIB1
immunostaining (> 30%).
DISCUSSION
This study shows for the first time, to the best of our knowledge,
the feasibility of an extensive structural and quantitative analysis
of TP53 on material obtained from FNA. The same material
allowed us to perform DNA analysis and compare both molecular,
molecular-cytogenetic and DNA content data to a number of
routinely used immunocytochemical-based parameters.
Although a statistically significant correlation was observed
between p53 overexpression and TP53 mutation (P = 0.004), and
the observed immunoreactivity pattern fitted fully with the charac-
terized mutation type, the results clearly show a definitively higher
informativity of molecular over immunophenotypic analysis. In
fact, no ICC reaction was observed in the four cases harbouring
TP53 mutations. Two ofthese false-negative ICC results (case nos.
20 and 26) were generated as a consequence of premature stop
codons that determine the synthesis oftruncated proteins and thus
render ICC detection impossible. In addition, we did not find
immunoreactivity in case numbers 30 and 10, despite TP53
missense mutations at codons 248 and 220 respectively. The
results observed in case 30 are in agreement with the hypothesis
reported by Greenblatt et al (1994), who observed that mutants at
codon 248 (Arg--Trp), implying this particular amino acid
change, maintain apparent wild-type conformation by antibody
analysis but acquire mutant transactivation function. The discrep-
ancy between ICC and molecular results in case number 10 is diffi-
cult to explain as the potential functional significance of this
mutation has not yet been verified.
In view ofall the above, and taking into consideration the patient
selection, the failure of immunophenotyping to detect mutations
closely mirrors that observed for histology-based material (Dunn et
al, 1993; Aas et al, 1996; Sjogren et al, 1996). This observation not
only indicates that ICC alone is an insufficient and unreliable indi-
cator ofp53 gene mutations in breast carcinoma, but also points out
a significant agreement between the present FNA-based data and
those obtained from conventional histological samples.
In one case (no. 6), molecular results did not coincide with p53-
positive immunostaining. This might be due to a mutation localized
in exons outside the screening area (exons 5-8). Approximately
10-20% of TP53 gene mutations have been found in exons 1-4 or
9-11 (Soussi et al, 1994; Hartmann et al, 1995). However, muta-
tions in other genes coding for proteins involved in the p53
pathway (Momand et al, 1992; Righetti et al, 1996) or the presence
ofp53-interacting proteins may also contribute to p53 stabilization.
Furthermore, DNA sequencing highlighted that seven out of ten
mutations, three of which showed no immunoreactivity, affected
the central part of the gene, which includes the zinc-binding
domains L2 (codons 163-195) and L3 (codons 236-251).
TP53 molecular and FISH analyses were successfully combined,
allowing the detection of four cases with deletion of one TP53
allele; three of them presented, therefore, only one TP53 normal
allele and are, in case ofa subsequent TP53 mutation, at higher risk
ofp53 loss offunction. The remaining case presented both deletion
and mutation (Figure 1), which, with the homozigous mutation,
represents the most tumorigenic situation (Solomon et al, 1991). In
this particular situation, the significance of the presence of only
p53-mutated protein in tumour cells has not yet been fully
explored. A possible anomalous transactivating activity of p53-
mutated complexes might confer a different biological behaviour
to the affected cells. The present approach could potentially reveal
more such cases; further analysis would clarify this point.
The rationale for comparing TP53 alterations with DNA
analysis stems from the in vitro and in vivo evidence showing that
loss, or inactivation, of TP53 can be associated with unstable
tetraploid cells that are predisposed for the development of aneu-
ploid populations (Cross et al, 1995). Although in the present
series, 17 DNA aneuploid cases showed no TP53 mutations, indi-
cating the possibility ofredundant control mechanisms for genetic
stability, it is worth mentioning that all nine cases harbouring TP53
mutations showed aneuploid DNA content, and two out of three
hypertetraploid cases belonged to the TP53-mutated cases.
Furthermore, the results support a close correlation between aneu-
ploidy, high MIB1 value, high cytological grade and show that
MIB 1 may usefully complement grading by contributing to a more
accurate definition of the grey zone represented by grade II and
may positively affect cytological diagnosis (Pinder et al, 1995). In
fact, similarly to grade III, all grade II cases with a high MIB1
value fell within the aneuploid group.
In conclusion, molecular analysis appears to be mandatory to
acquire more precise information, not only regarding the type of
TP53 mutation but also the TP53 genomic status for the discrimi-
nation between wild-type-mutant complexes (dominant-negative
effect) and mutant-mutant proteins, which could confer different
biological properties to the tumour cells; FNA seems to be suitable
for this type of study. Complementary DNA analysis stresses the
strong predictivity of aneuploidy for grading either represented as
grade III or grade II and critically supplemented by ICC-MIB1
assessment.
The results demonstate that PCR-SSCP and sequencing, FISH
and DNA image analyses can be simultaneously and successfully
performed on FNA material, making FNA a reliable and helpful
tool for the prognostic assessment and the therapeutic management
ofbreast cancer patients.
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